69 results about "Human bladder" patented technology

The invention provides sgRNA and a gene vector for inhibiting bladder cancer by targeting human lncRNA-UCA1 and an application of the sgRNA; specifically, sgRNA sequences of an lncRNA-UCA1 gene and a PD-1 gene suitable for CRISPR-Cas9 targeted splicing are designed; by transforming plasmids of specific splicing lncRNA-UCA1 gene and CRISPR-Cas9 nuclease gene into human bladder cancer cells, the expression of the lncRNA-UCA1 gene drops so as to inhibit the growth of tumor cells; and the plasmid, together with a human PD-1 gene targeted knockout vector, is transformed into a humanized mouse model of bladder cancer transplanted tumor, so as to obviously inhibit the growth of tumors. According to the invention, the vector is simple in preparing steps, the sgRNA is good in targeting property and the CRISPR-Cas9 is high in knockout efficiency.

The present invention relates to a device (40) for urinary catheterisation. In particular, the invention relates to a device comprising an oblong member (1) for opening the human bladder and a guide member (2) for manipulating the oblong member. The guide member may be provided in a bend configuration e.g. being curled or folded, such that the size of the device is small in comparison with the size of known catheters, especially in comparison with existing catheters for male users.

An intermittent urinary catheter assembly (20) comprises a catheter tube (22) having a proximal insertion end (24) and a distal end (26) remote from the proximal insertion end and a lumen (28) which extends from at or near the proximal insertion end to the distal end for draining urine from a human bladder. The intermittent urinary catheter assembly includes a urine discharge sleeve (34) associated with the discharge opening (30) of the catheter tube, and the urine discharge sleeve has a compact stowed configuration and is extendable into a deployed configuration for directing urine flow. Alternatively, an adapter assembly (50″) comprises a fitting or nipple (52″) having a urine passageway for insertion into a funnel (40″) associated with a urine discharge end of an intermittent urinary catheter, and a discharge funnel (42″) associated with the fitting or nipple, and an extendable urine discharge sleeve (34″) within the discharge funnel.

The invention relates to a method for detecting a circular RNA for bladder cancer screening and an application thereof; in particular, with use of a circular RNA chip, through difference analysis, the circRNA significantly highly expressed in a human bladder cancer tissue is screened and is named as cRNA-ZFR. Compared with a normal tissue, the cRNA-ZFR is significantly highly expressed in the human bladder cancer tissue, and the cRNA-ZFR is further confirmed to have the expression quantity in the human bladder cancer tissue significantly higher than that of the normal tissue in large-sample fluorescent quantitative PCR experiments. The novel cRNA-ZFR provides a new idea for further study of pathogenesis of bladder cancer, and also provides a new target for early screening and prognosis monitoring of bladder cancer.

The invention discloses a method for establishing a human bladder transitional cell carcinoma cell line and a mouse model of bladder carcinoma tissue recombination functional reconstruction. The method includes the primary cell culture, immortalized cell line identification, tissue reorganization and planting, HE staining, and immunohistochemistry. The invention establishes a novel stable human bladder transitional cell carcinoma cell line, and uses the cell line to construct the mouse model of bladder carcinoma tissue recombination functional reconstruction. The occurrence and development of bladder carcinoma are simulated in mice. The method researches on the biological behavior of bladder carcinoma from in vitro molecular and cell biology and in vivo animal models, and provides an effective tool for the discovery of new biomarkers and therapeutic measures.

The invention relates to application of protosappanin B, in particular to application of a 0.2 to 2.4 percent protosappanin B solution in preparation of bladder cancer resistant perfusion fluid. For filling up the research blank of the protosappanin B at home and abroad, the invention provides new application of the protosappanin B. Human bladder cancer cell strains T24 or mouse bladder cancer cell strains BTT are inoculated to mouse bodies to form bladder cancer, and the mice are grouped and respectively subjected to experiments with injection water, mitomycin and the protosappanin B; experiment results show that the lives of the mice injected with the mitomycin and the protosappanin B are prolonged, the tumor weight is reduced, and a tumor inhibiting effect is achieved; and the protosappanin B has a remarkable bladder cancer inhibiting effect, and can be widely applied to preparation of the bladder cancer resistant perfusion fluid.

The invention discloses a special urine bag for a critical patient carrying with an indwelling ureter for a long time. A main body comprises a ureter and a urine bag and further comprises a pressure sensor, a pressure valve, a flow sensor, a urine component detection element, a weight sensor, an alarm and a communication module. Since the pressure sensor and the pressure valve are arranged on the traditional urine bag structure, the pressure sensor can detect the internal pressure of a human bladder, so that drainage is realized in cooperation with the pressure valve and the effect of simulating a human normal bladder function is achieved. Since the flow sensor and the urine component detection element are arranged, urine drainage amount and urine components at each time can be acquired and analyzed and can be transmitted to an intelligent terminal, so that the health condition can be always monitored, and doctors can know the illness state of the patient in the first time and change the treatment plan in time. Since the weight sensor and the alarm are arranged at the lower end of the urine bag, when the urine amount in the urine bag exceeds the range set by nurses, an alarm can be given out.

The invention mainly belongs to the technical field of tumor immunology, and particularly relates to a human urinary bladder carcinoma marker AG-CD71 and a monoclonal antibody ABC71 for preventing AG-CD71. The human urinary bladder carcinoma marker AG-CD71 provided by the invention is an abnormal glycosylated transferrin receptor TFRC; the abnormal glycosylated transferrin receptor TFRC refers tothat the TFRC carriers a saccharide structure Fucal-4(GlcNAcb1-3) as an epitope; the invention provides an antibody for the human urinary bladder carcinoma marker AG-CD71; the antibody is a specific monoclonal antibody ABC71 for preventing the human urinary bladder carcinoma marker AG-CD71; the monoclonal antibody is secreted from a hybridoma cell strain of which the preservation number is CGMCC No.14312. Cell and histology levels show that the ABC71 is capable of specifically recognizing human urinary bladder carcinoma cells and human urinary bladder carcinoma tissue. The monoclonal antibodyABC71 for preventing the human urinary bladder carcinoma has an intense positive reaction with human urinary bladder carcinoma tissue and has a negative reaction with normal human urinary bladder tissue.

Experiments designed to define the differences between the 21 oncogene of DNA isolated from human bladder cancer cells and its corresponding proto-oncogene are described herein. Also described is the determination of the difference between the rat neu oncogene and its corresponding proto-oncogene. Also described are nucleic acid probes reactive with regions of the proto-oncogene or oncogene, as are methods for their use in detecting the occurrence of the two types of genes. Antibodies specific for gene products encoded by the neu genes are also described, as are methods for their use.

The present invention is based, at least in part, upon discovery of a number of miRNAs having expression that significantly correlates with bladder cancer, including certain stages or types of bladder cancer, as well as with bladder cancer survival and/or responsiveness to bladder cancer therapies. Accordingly, the present invention features the identification and use of miRNAs to detect, diagnose and/or predict the course, progression or therapy responsiveness of bladder cancer. Kits for performing such assessments, and for administering therapeutic agents to subjects diagnosed with bladder cancer or certain forms of bladder cancer using the methods of the invention, are also featured.

The invention discloses an automatic identification regulator for bladder irrigation liquid, which comprises a urine color detector arranged on a urine dropping pipe. The urine color detector is connected with a microprocessor for receiving urine color information of the urine color detector, the microprocessor is connected with a stepping motor for receiving control signals of the microprocessor, the stepping motor is connected with a stepping regulating valve, and the stepping regulating valve is installed on an irrigation pipe for conveying the irrigation liquid to the human bladder and controls the conveying of the irrigation liquid. The automatic identification regulator for the bladder irrigation liquid is reasonable in structure and capable of automatically regulating dropping speed according to the color of the irrigation liquid at any time, thereby simplifying nursing operation and reducing nursing strength and operation pollution.

The invention discloses a method for establishing a bladder cancer in-situ model of a nude mouse. The method is characterized by comprising the following steps of: narcotizing a female nude mouse superficially, and inserting a urethral catheter with a side hole into a bladder from a urethral canal, so that negative pressure is formed in the urethral catheter continuously; penetrating a cutter into the urethral catheter, and adjusting the positions of a cutting inclined plane and the side hole of the urethral catheter; cutting under the negative pressure to cut part of mucous membrane layers off, so that the lower layer of a bladder mucous membrane is exposed to form a local wound surface; and pouring human bladder cancer cell suspension which is in the logarithm growth period into a bladder cavity of the nude mouse and reserving for a period of time, discharging the cell suspension out, and establishing the superficial bladder cancer model after 7 days. Compared with the conventional electrocauterization method, the conventional chemical medicinal corrosion method and the conventional bladder puncture intracavity cutting method, the method has the advantages that molding assemblies are low in production cost, and the method for establishing the bladder cancer model is good in effect, the device is easy to operate, the time is short, the nude mouse has little pain, and death caused by anesthesia, operation strike and infection is reduced obviously.

The invention discloses an automatic urine specimen collecting system device which comprises a urinary catheter. The top of the urinary catheter is inserted into the human bladder, a branch tube is arranged on the surface of the urinary catheter, a collecting bin is fixedly connected to the surface, close to the bottom, of the branch tube hermetically, a first shaft driven to rotate by a power mechanism limitedly rotates on the inner wall of the collecting bin, and the power mechanism is electrically connected with a microprocessor. The surface, close to the rear end, of the first shaft penetrates through the rear side of the collecting bin and is fixedly connected with a first wheel, the surface of the first wheel is sleeved with a transmission belt, and the inner wall, close to the bottom, of the collecting bin is fixedly connected with a first check valve. By adopting the matched use of the structures, the problem is solved that it is difficult to collect urine regularly due to thefact that the urine in different time periods is mixed in a urine bag in the actual use process; the problem is solved that the collection of a urine sample in each time period is also difficult to achieve, manual operation also consumes time and labor and accordingly inconvenience is brought in use.

The invention provides human bladder cancer cells capable of realizing multi-organ metastasis, and more specifically relates to a novel multi-organ metastasis bladder cancer cell line CH-2 which is preserved in China Center for Type Culture Collection (CCTCC) on August, 26th, 2013. Preservation number of the novel multi-organ metastasis bladder cancer cell line CH-2 is CCTCC No.C2013129. Cellular morphology and serial subcultivation characteristics of the novel multi-organ metastasis bladder cancer cell line CH-2 are stable; tumor forming performance is excellent; metastasis performance is high; the novel multi-organ metastasis bladder cancer cell line CH-2 can be used for generating high aggressive bladder cancer cells capable of realizing multi-organ metastasis, can be combined with low aggressive bladder cancer cell lines, and is used for selecting medicines used for treating bladder cancer with different characteristics, and selecting genes relating to metastasis.

The invention discloses an application of a phenyl ether compound as shown in general formula I in preparation of antitumor drugs. The compound of the general formula I has very good antitumor activity, and especially has excellent activity for human bladder cancer LNCap, T24, J82 and human prostate cancer PC-3.

The invention discloses a human bladder cancer gemcitabine drug-resistant cell strain, which is named as a human bladder cancer gemcitabine drug-resistant cell strain 5637-GEM-A1, and the preservation number of the human bladder cancer gemcitabine drug-resistant cell strain is GDMCC No: 61948. The drug-resistant index of the human bladder cancer drug-resistant cell strain meets the evaluation requirements of drug-resistant strains, and the human bladder cancer drug-resistant cell strain has important application prospects in the aspects of researching a bladder cancer drug-resistant mechanism, excavating a bladder cancer gemcitabine drug-resistant target, reversing bladder cancer cell drug resistance and guiding medication of patients.

The invention relates to a hybridoma which can generate a monoclonal antibody against human bladder cancer, and parental cells of which are B lymphocytes of a mouse and myeloma cells of the mouse immunized by E-J cells of a human bladder cancer cell line. The invention also relates to purposes and a preparation method of the hybridoma, the monoclonal antibody generated by the hybridoma, a directional drug against bladder cancer and a bladder cancer immunological diagnostic reagent and a preparation method of the directional drug. The antibody part of the directional drug serves as the monoclonal antibody against human bladder cancer. The diagnostic reagent is composed of an E-J cell lysis liquid of the human bladder cancer cell line and the monoclonal antibody DTB against human bladder cancer coated on an enzyme label plate, and the bladder cancer antigen in urine exfoliated cells is examined through adopting the competitive ELISA method. The specificity of the antibody of the hybridoma is strong; the tumor killing function of the directional drug of the hybridoma is strong without drug tolerance but good specificity; and the diagnostic reagent of the hybridoma has the advantages of damage resistance, high sensibility and specificity as well as convenience and quickness.

The invention provides an application of PPM-18 in inducing apoptosis of bladder cancer cells by activating intracellular reactive oxygen species (ROS). The PPM-18 significantly inhibits the viabilityof bladder cancer cell; PPM-18 promote cell apoptosis by inducing ROS production in bladder cancer cells; and the PPM-18 significantly inhibits the growth of human bladder cancer subcutaneous tumorsand prolongs the survival cycle of mice with subcutaneous tumors. At the same time, PPM-18 has very lower toxicity to normal human hepatocyte. In addition, PPM-It can be synthesized chemically, with lower cost, and can be used as a new drug for treating bladder cancer.

The invention relates to a fingerprint spectrum consisting of small RNAs and application thereof to diagnosis of bladder cancer. The fingerprint spectrum consisting of a plurality of RNAs can very effectively distinguish a bladder cancer tissue and a paracancerous tissue with high sensitivity and strong specificity, and can be effectively applied to the diagnosis of the bladder cancer.

The invention provides a genetic marker related to human bladder cancer, and a detection method and application thereof. The genetic marker is located in the ZNF83 gene sequence, gene mutation occursat the genetic marker, and the mutation site is selected from one or more of chr19:57808752T>A, chr19:57808761T>C and chr19:57808819G>T. Mutation of the ZNF83 gene is one of the indicators of poor prognosis of bladder cancer, and can be used as an auxiliary index for the diagnosis of bladder cancer. The ZNF83 gene can be used as a new effect target for the treatment of bladder cancer.

The invention provides application for directionally killing human bladder cancer cells T24 through a coupling CD3*B7H3 dual-specificity antibody, particularly, the coupling CD3*B7H3 dual-specificityantibody can enhance the T24 bladder cancer cell killing effect of the activated T cell (ATC), and an immunity treatment target spot is provided for bladder cancer targeting treatment. Researches prove that B7H3 can achieve high expression in the T24 bladder cancer cell; compared with the ATC of the uncoupled CD3*B7H3 dual-specificity antibody, the capability of the ATC combined with the CD3*B7H3dual-specificity antibody for directionally killing the T24 bladder cancer cells is enhanced, and the remarkable cell toxin activity is achieved for the T24 bladder cancer cells. When co-culture is performed on the condition that the effective target ratio of the ATC combined with the CD3*B7H3 dual-specificity antibody to the tumor cells is 10:1, the killing effect is remarkably increased. Meanwhile, the level of the ATC combined with the CD3*B7H3 dual-specificity antibody for secreting a gamma-interferon (IFN-gamma) and an alpha-tumor necrosis factor (TNF-alpha) is increased.